SHAKER HEIGHTS, Ohio--(BUSINESS WIRE)--VION Biosciences ("VION"), a life sciences company building differentiated capabilities across research, diagnostics, and drug development workflows, today announced the closing of its acquisition of Cellular Technology Limited ("CTL"), a provider of functional immune monitoring analyzers, software, consumables, and services.
NASHVILLE, Tenn.--(BUSINESS WIRE)--VION Biosciences, a life science platform company focused on specialty materials in the life science research, diagnostics, and drug discovery spaces, announced its January 2025 acquisition of San Francisco area-based BioAssay Systems, a biotech company that develops and offers innovative high-throughput assay solutions for life sciences and drug discovery. This acquisition serves as the fourth investment under the VION platform, continuing its growth in developing proprietary products for life science research.
CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--VION Biosciences, a life science platform company focused on specialty materials in the life science research, diagnostics, and drug discovery spaces, today announced Vince Stoyanov as its Chief Strategy and Development Officer. He will lead corporate development, mergers and acquisitions (M&A), and other related corporate functions, bringing both expertise and continued energy to VION at a critical moment in its expansion efforts.
CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--VION Biosciences, a life science platform company focused on specialty materials in the life science research, diagnostic, and drug discovery spaces, announces its second acquisition this August with the acquisition of Ansh Labs, a biotechnology company that focuses on the development, production, and distribution of high-quality immunoassay kits and reagents for research and clinical diagnostics. Based out of Houston, TX, Ansh positions VION to better serve the diagnostic market, with its products enabling customers to conduct important research in various clinical diagnostic areas. This is the third investment under VION Biosciences, Iron Path Capital’s roll-up platform in the life science sector led by life science industry veteran, Mark Thornton.
CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--VION Biosciences, a life science platform company focused on specialty reagents in the life science research, diagnostic, and drug discovery space, announced the recent acquisition of Salt Lake City-based Echelon Biosciences, a trusted supplier of critical materials, notably lipid-based excipients, to its growing portfolio. This acquisition serves as the second investment under VION Biosciences LLC (“VION Biosciences”), Iron Path Capital’s roll-up platform in the life science sector led by life science industry veteran, Mark Thornton.
VION Biosciences
Empowering a World of Discovery
Partner with Vion Biosciences to drive innovation in life sciences and beyond. Let us provide the solutions to power your success.
